Best for Longevity

Creatine monohydrate demonstrates strong evidence for improving muscle mass, strength, and physical function in older adults when combined with resistance training, with emerging evidence for cognitive benefits in aging populations. However, direct evidence specifically linking creatine to longevity outcomes is limited.

Collagen peptides demonstrate strong evidence for improving skin health markers (hydration, elasticity, wrinkles) across multiple well-designed human RCTs, with consistent replication and clinically meaningful effect sizes. Evidence for musculoskeletal and muscle function benefits in aging populations is moderate but emerging.

Ginkgo biloba extract (EGb 761), particularly at 240 mg/day, demonstrates clinically meaningful improvements in cognitive function and activities of daily living in humans with cognitive impairment and dementia across multiple randomized controlled trials. Evidence is strong but primarily addresses cognitive symptoms rather than proven lifespan extension.

Abaloparatide reduces fracture risk and increases bone mineral density in postmenopausal women and men with osteoporosis, based on multiple randomized controlled trials and meta-analyses. Evidence strongly supports its efficacy for fracture prevention, which is relevant to longevity through reduction of fracture-related morbidity and mortality in aging populations.

Ashwagandha shows probable efficacy for longevity-related outcomes in humans, with multiple RCTs demonstrating improvements in physical performance, muscle strength, cognitive function, and inflammatory markers. However, evidence is limited by small sample sizes, short study durations (8-12 weeks), and lack of long-term follow-up data directly measuring lifespan or true longevity endpoints.

Thymosin Alpha-1 shows probable efficacy for supporting immune function in aging, with multiple human studies demonstrating improved vaccine responses and immune cell counts, but evidence is limited by small sample sizes, lack of independent replication, and absence of direct longevity outcome measures.

Tesamorelin shows probable but not conclusive benefits for longevity-related outcomes in humans, with consistent effects on body composition and emerging evidence for cognitive function in aging and HIV populations. However, efficacy for core longevity markers remains unproven, and most cognitive benefits show trends rather than statistically significant improvements.

GHRP-2 robustly stimulates GH and IGF-I secretion in humans across multiple RCTs, but direct evidence linking these acute hormonal changes to longevity outcomes is absent. The compound demonstrates consistent, reproducible GH-releasing efficacy in controlled human studies, yet no trial has measured lifespan, healthspan, or age-related mortality endpoints.

Follistatin 344 shows probable efficacy for longevity-related outcomes through improvements in sarcopenia markers and muscle quality in humans, supported by 4 RCTs demonstrating consistent increases in the follistatin/myostatin ratio. However, evidence is limited by small sample sizes, short intervention durations (8-12 weeks), and lack of direct longevity outcome measurement.

Thymalin demonstrates probable efficacy for longevity in humans based on one moderate-quality RCT showing 2.0-2.1-fold mortality reduction over 6-8 years, supported by consistent animal studies and mechanistic evidence. However, the single human RCT lacks independent replication and detailed methodological reporting, preventing a higher evidence tier.

Cerebrolysin shows probable efficacy for longevity and age-related cognitive decline based on multiple human studies and consistent animal data, but evidence remains limited by small sample sizes, short treatment durations, and lack of independent replication in large RCTs.

Ibutamoren (MK-677) demonstrates probable efficacy for longevity-related outcomes by restoring growth hormone and IGF-I axis function in elderly subjects. However, evidence is limited to 3 small human RCTs with short durations, and no direct lifespan or mortality data exists to prove actual longevity benefit.

GLP-1 receptor agonists show plausible mechanisms and suggestive epidemiological evidence for longevity-related benefits (reduced neurodegeneration, improved cardiovascular and metabolic health, reduced ocular aging), but human proof of longevity extension remains absent. Current evidence is mixed: mechanistic studies and observational data support anti-aging potential, but concerns about muscle mass loss and facial aging complicate the longevity benefit profile.

Argireline demonstrates probable efficacy for reducing wrinkles and skin aging signs in humans, supported by 2 RCTs showing ~48% anti-wrinkle effects and improvements in skin texture. However, evidence is limited by small sample sizes, short treatment durations (4-6 weeks), and lack of independent replication of the primary RCT findings.

Omega-3 fatty acids show probable benefits for longevity-related outcomes including muscle mass, cardiovascular health, and cognitive function in humans, but efficacy is not conclusively proven due to inconsistent results, modest effect sizes, and limited large-scale RCT data.

Magnesium supplementation shows probable benefits for longevity through multiple biological mechanisms including telomere preservation, mitochondrial function, and reduced inflammation, but human evidence remains limited to small observational studies and short-duration RCTs without large-scale, long-term mortality data.

Vitamin D3 supplementation shows probable but not conclusive benefits for longevity-related outcomes in humans, with multiple RCTs demonstrating modest effects on intermediary markers (telomere attrition, diabetes risk, bone health) but limited direct evidence of lifespan extension or all-cause mortality reduction.

Curcumin shows probable benefits for longevity-related outcomes including vascular function, oxidative stress reduction, and cognitive aging in humans, but efficacy remains inconclusive due to small sample sizes, inconsistent results across studies, and limited independent replication.

NMN consistently elevates blood NAD+ levels in humans and shows promising effects on metabolic health, insulin sensitivity, and muscle function in multiple small-to-moderate RCTs. However, direct evidence for longevity extension in humans is absent; efficacy for aging-related diseases is probable but not conclusively proven.

CoQ10 shows probable efficacy for longevity-related outcomes, particularly mitochondrial function and age-related conditions, but evidence remains limited to small human trials and mechanistic studies without large-scale, long-term RCTs directly measuring lifespan or healthspan endpoints.

Probiotics show probable benefits for longevity-related outcomes in humans, with evidence for improved muscle mass, immune function, and cellular aging markers (telomere length). However, evidence remains mixed and limited by small sample sizes, inconsistent effect sizes, and a lack of long-term follow-up studies demonstrating actual lifespan extension.

Tongkat Ali shows probable efficacy for longevity-related outcomes in humans, with consistent improvements in testosterone, muscle strength, mood, and stress markers across multiple RCTs. However, evidence is limited by small sample sizes (most n<150), short intervention periods (4-12 weeks), and lack of direct longevity endpoints (lifespan, mortality, aging biomarkers).

Aged garlic extract shows probable efficacy for cardiovascular health markers related to longevity, with consistent positive effects on blood pressure and vascular calcification demonstrated in 2 human RCTs and a meta-analysis. However, effect sizes are modest and long-term longevity outcomes have not been measured.

Vitamin C shows probable benefits for longevity through antioxidant and anti-aging mechanisms supported by multiple human observational studies and consistent animal evidence, but lacks large-scale, well-controlled human RCTs needed to establish definitive efficacy.

B vitamin complex shows probable benefit for longevity-related outcomes, particularly cognitive preservation and slowing brain atrophy in aging populations. Evidence is moderate but limited primarily to cognitive and neurological endpoints; broader longevity claims remain largely mechanistic or observational.

Vitamin B12 shows probable benefits for longevity-related outcomes including cognitive function, brain volume preservation, and reduced neurodegeneration markers in older adults, but evidence is mixed and mostly observational with limited large-scale RCT confirmation.

Spermidine shows probable efficacy for longevity in model organisms and emerging mechanisms in humans, with one small RCT demonstrating cognitive benefits. However, robust human evidence is limited to a single trial with modest sample size and cognitive (not lifespan) outcomes.

Urolithin A demonstrates probable efficacy for longevity through mitophagy activation and mitochondrial health improvement in humans, with multiple RCTs showing meaningful improvements in muscle strength, endurance, and biomarkers of aging. However, evidence is limited by small sample sizes, short intervention periods (4 months maximum), and lack of long-term survival or lifespan outcome data.

Pycnogenol shows probable efficacy for supporting healthy aging through multiple mechanisms including antioxidant and anti-inflammatory effects, with demonstrated benefits for cardiovascular health, cognitive function, and skin aging in human RCTs. However, evidence remains limited by small sample sizes, short intervention periods, and lack of direct mortality or lifespan data.

Nattokinase shows probable efficacy for longevity-related cardiovascular outcomes in humans, with demonstrated benefits for blood pressure reduction and vascular inflammation markers. However, evidence is limited to 3 human RCTs with small-to-moderate sample sizes and relatively short intervention periods, and the connection to actual longevity remains unproven.

Epicatechin shows probable benefits for longevity through multiple mechanisms including muscle preservation, mitochondrial function, and antioxidant effects. However, human evidence remains limited to small studies and observational designs; the largest human RCTs (COSMOS) found null or minimal effects on key aging biomarkers.

Pomegranate extract shows probable but not conclusive benefits for longevity-related markers in humans, with evidence of improved inflammatory markers, IGF-1 levels, and cognitive function in older adults. However, human trials are small (n<100), short-term (12 weeks), and mostly from a single research group, limiting definitive claims about actual lifespan or healthspan extension.

Cistanche shows probable efficacy for longevity-related outcomes in humans, with 4 RCTs demonstrating improvements in memory, muscle function, and walking ability in aging populations. However, evidence is limited by small sample sizes (n=26–117), short intervention periods (4–12 weeks), and lack of independent replication of core longevity endpoints.

Rapamycin shows probable efficacy for longevity through mTOR inhibition in both animal models and humans, with consistent mechanistic support and some clinical evidence, but human studies remain limited in scale and duration. Most efficacy data comes from animal studies; human trials are small, pilot-stage, or observational.

Whey protein shows probable but inconsistent benefits for longevity-related outcomes, particularly muscle mass and strength in older adults when combined with resistance training. However, effects on cardiometabolic markers and cognitive function are modest and not universally demonstrated across studies.

Bacopa monnieri shows probable efficacy for cognitive function in aging adults based on multiple human RCTs, but evidence for longevity-specific outcomes (telomere length, lifespan extension) remains largely preclinical. Human studies demonstrate consistent cognitive benefits, though sample sizes are modest and long-term effects are understudied.

CDP-Choline shows probable benefits for age-related cognitive decline and memory function in humans, with consistent positive effects across multiple RCTs and observational studies. However, evidence remains limited by small sample sizes, short treatment durations, and lack of high-quality meta-analytic confirmation, preventing higher-tier classification.

Huperzine A shows probable efficacy for cognitive function and dementia-related decline in humans, supported by multiple clinical trials and meta-analyses, but evidence is limited by small sample sizes, lack of large-scale RCTs, and unclear disease-modifying effects for longevity specifically.

PQQ shows probable efficacy for longevity in animal models and limited human cognitive/mitochondrial studies, with consistent mechanistic evidence for anti-aging pathways. However, human evidence remains sparse (3 RCTs, mostly small) and direct lifespan extension in humans is unproven.

Centrophenoxine shows probable efficacy for cognitive performance and dementia symptoms in humans based on multiple RCTs, but evidence is limited by small sample sizes, short trial durations (3 months), and lack of independent replication by diverse research groups. Longevity claims remain mechanistically plausible but unproven in humans.

Acetyl-L-carnitine (ALC) shows probable benefit for longevity-related outcomes including frailty progression, cognitive decline, and mitochondrial function in humans, but efficacy is not conclusively proven. Evidence comes from a limited number of small-to-moderate human RCTs with inconsistent study designs and outcomes.

Glycine supplementation shows consistent lifespan extension in animal models and likely improves longevity-related markers in humans through glutathione synthesis and oxidative stress reduction, but human evidence remains limited to small studies and mechanistic observations without large RCTs demonstrating clinical longevity benefit.

Beta-alanine supplementation shows probable efficacy for improving exercise capacity and cognitive function in older adults, with consistent positive results across multiple human RCTs. However, evidence for direct longevity outcomes is absent; benefits appear primarily mediated through enhanced physical performance and muscle carnosine content rather than proven lifespan extension.

L-Citrulline shows probable efficacy for longevity-related outcomes via improved endothelial function and vascular health in humans, but evidence is limited to small RCTs and observational studies with modest effect sizes and short durations. No long-term lifespan data exists in humans.

HMB supplementation shows probable but not conclusive efficacy for longevity-relevant outcomes in older adults, primarily through modest improvements in muscle strength and physical function when combined with resistance training. Effects are clinically meaningful in specific contexts but inconsistent across outcomes and populations.

BCAAs show probable benefits for physical function and muscle mass in older adults when combined with exercise, but evidence for longevity per se is limited and mixed. Elevated BCAA levels are associated with increased type 2 diabetes risk, complicating the longevity narrative.

L-arginine shows probable but not conclusive efficacy for longevity-related outcomes in humans, with demonstrated benefits for endothelial function and vascular health in elderly populations. However, recent evidence suggests chronic supplementation may have detrimental effects on aging-related kidney function, creating a concerning risk-benefit profile.

Leucine supplementation shows probable efficacy for preserving muscle mass and function during aging and disuse, with consistent benefits demonstrated across multiple human studies. However, evidence remains limited by small sample sizes, short durations, and mixed results on strength outcomes, preventing a higher confidence tier.

Dulaglutide shows promise for longevity-related outcomes through cardiovascular protection and cognitive benefits in humans with type 2 diabetes, but evidence is limited to observational studies and exploratory analyses rather than dedicated longevity trials.

Thymopentin demonstrates probable efficacy for longevity-related outcomes in humans by improving immune function and cardiac health in aging populations, supported by 4 human RCTs showing consistent immune modulation and clinical improvements. However, evidence is limited by small sample sizes, short treatment durations, and lack of direct lifespan extension data in humans.

Alpha-ketoglutarate (AKG) shows promise for slowing biological aging in humans, with one RCT reporting an 8-year reduction in DNA methylation age after 7 months, but evidence remains limited to small, short-duration studies without consistent independent replication.

Vitamin B3 (nicotinamide and its precursors like nicotinamide riboside) shows probable efficacy for longevity through multiple mechanisms in humans, supported by several small-to-moderate RCTs and observational studies. However, evidence remains limited by small sample sizes and short follow-up periods, and no large-scale, long-term human trials demonstrating actual lifespan extension exist.

Folate supplementation shows probable benefit for cognitive function and dementia prevention in humans, supported by multiple small-to-moderate RCTs and observational studies, but evidence remains limited by small sample sizes, short durations, and lack of large-scale replication.

Lutein shows probable benefits for eye health and macular pigment density in aging populations, with emerging evidence suggesting cognitive benefits. However, evidence for actual longevity extension is absent; studies focus on age-related disease prevention rather than lifespan extension.

MCT oil shows probable efficacy for supporting brain health and cognitive function, particularly in people with mild cognitive impairment and Alzheimer's disease, through increased ketone availability to the brain. However, evidence is mixed in healthy older adults and limited for general longevity.

Beetroot supplementation shows probable benefits for cardiovascular function and muscle quality in older adults, particularly postmenopausal women, but evidence for longevity as a primary outcome is absent and cognitive benefits remain inconclusive.

TB-500 shows promising anti-aging effects in animal models, including cellular senescence reversal and tissue regeneration, but lacks rigorous human trials demonstrating proven longevity benefits.

GHK-Cu shows promise for longevity-related endpoints in animal models, particularly for cognitive decline and neuroinflammation, but lacks human clinical trials demonstrating efficacy for lifespan or aging outcomes. Evidence is emerging but unproven in humans.

Epithalon shows consistent longevity-extending effects in animal models (fruit flies, rodents, primates) and appears to work through epigenetic mechanisms and pineal gland regulation. However, no human randomized controlled trials demonstrate efficacy for lifespan extension or longevity in humans.

DSIP shows consistent longevity-related benefits in rodent models, including extended lifespan in the oldest mice, reduced cancer incidence, and improvements in aging biomarkers. However, only one small human observational study exists, showing quality-of-life improvements in elderly diabetics but no direct longevity data. Efficacy in humans for longevity remains unproven.

MOTS-c shows biologically plausible mechanisms for longevity and age-related disease prevention, but human efficacy for longevity extension has not been demonstrated. Evidence is limited to animal models, small observational human studies showing correlations, and mechanistic reviews; no human RCTs testing longevity outcomes exist.

SS-31 (elamipretide) shows consistent mechanistic benefits for mitochondrial function in animal and cell models, with emerging evidence from one human RCT in primary mitochondrial myopathy. However, direct evidence for longevity extension in humans is absent; efficacy remains plausible but unproven in living humans.

Sermorelin (GHRH analog) shows plausible mechanisms for longevity support in animal models, including increased telomerase activity and reduced tumor incidence in mice, but evidence is limited to 2 small human RCTs focusing on immune and metabolic outcomes rather than lifespan or aging markers.

LL-37 shows plausible mechanisms for longevity-relevant processes (autophagy, inflammation, cardiovascular protection) but lacks direct human evidence of lifespan extension or clinical longevity outcomes. Evidence is primarily mechanistic in animal models and cell cultures, with limited human observational data on age-related biomarkers.

Kisspeptin has been extensively studied in animal models and mechanistic reviews for reproductive aging and longevity-related processes, but there is no human RCT evidence demonstrating efficacy for longevity. Evidence is limited to 2 human observational studies focused on reproductive hormones, with the remainder being animal studies and reviews describing hypothetical mechanisms.

GHRP-6 reliably stimulates GH secretion in both young and elderly humans, but no studies demonstrate that this GH elevation translates to longevity benefits, lifespan extension, or meaningful anti-aging outcomes in humans.

Hexarelin consistently stimulates growth hormone secretion in humans and animals, but direct evidence that this translates to meaningful longevity benefits is absent. Most human studies demonstrate GH-releasing efficacy; animal studies suggest potential benefits to muscle and bone metabolism, but no lifespan or aging outcome data exists.

Melanotan 2 reduces body mass and fat mass in rats through activation of the central melanocortin system, with effects partially independent of caloric restriction. However, no human trials exist, and longevity effects are not directly studied—making efficacy for longevity entirely unproven.

Humanin shows plausible mechanisms for longevity extension in animal models and cell studies, with preliminary observational data in humans suggesting associations with healthspan and reduced disease markers. However, no human RCTs have demonstrated proven efficacy for extending lifespan or healthspan.

GDF11 shows promise for longevity-related outcomes in animal models and mechanistic studies, but human evidence remains extremely limited and mixed. Only 5 human RCTs exist in the 50-article dataset, with conflicting results on cardiovascular outcomes.

FOXO4-DRI shows consistent senolytic activity across multiple animal and cell-based models, selectively eliminating senescent cells through p53 pathway activation. However, no human randomized controlled trials exist; all human data is observational or mechanistic, limiting proof of efficacy for longevity in people.

VIP shows plausible mechanisms for supporting longevity-related processes like neurogenesis, neuroprotection, and immune regulation based on animal and mechanistic studies, but no human clinical trials demonstrating actual lifespan extension or meaningful longevity benefits exist.

Pinealon shows plausible geroprotective effects in small human observational studies and animal models, but efficacy is not proven. No randomized controlled trials exist, and human evidence is limited to observational designs with small samples.

Cortagen shows consistent mechanistic effects on chromatin structure and immune markers in aging cells and animal models, but no human efficacy trials for longevity exist. Effects are plausible but unproven in living humans.

Vilon shows plausible geroprotective effects supported by consistent animal and mechanistic studies, but efficacy for longevity remains unproven in humans. The two human RCTs are small, focus on disease-specific outcomes (diabetes complications) rather than lifespan, and lack direct longevity endpoints.

Cartalax (short peptides including AED, KED, KE, and AEDG) shows consistent effects on cellular aging markers in cell cultures and limited animal models, but no human clinical trials demonstrate efficacy for longevity. Evidence is restricted to in-vitro mechanistic studies and one animal review.

ARA-290 shows promise for cardiac health and frailty reduction in aging, but evidence comes from a single human RCT with incomplete reporting. Efficacy for longevity is plausible but not yet proven.

MGF shows consistent mechanistic activity in animal models and limited human data, but lacks rigorous human RCT evidence demonstrating efficacy for longevity. One human RCT exists showing MGF mRNA upregulation with resistance training, but no direct longevity or lifespan outcomes have been measured in humans.

Prostatilen is a peptide extract from prostate tissue proposed as a geroprotector, but evidence for longevity benefits remains preliminary. Only one animal study and one review examining tissue regeneration exist; no human longevity or lifespan data have been reported.

Cortexin shows neuroprotective and geroprotective mechanisms in animal models and limited human studies, but lacks rigorous, large-scale RCT evidence in humans specifically for longevity outcomes. Efficacy for extending lifespan or improving longevity is plausible but unproven.

NAC shows plausible anti-aging mechanisms in animal and cell models through ROS reduction and cellular stress resistance, but there is no direct human evidence demonstrating that NAC extends lifespan or improves longevity outcomes. One concerning animal study found chronic NAC actually accelerated aging in C. elegans.

Zinc shows plausible biological mechanisms for longevity through immune enhancement and reduction of age-related decline, but robust human evidence directly demonstrating lifespan or healthspan extension is absent. Most evidence is mechanistic or in animal models; human studies focus on age-related diseases rather than longevity itself.

Berberine shows promise for longevity through multiple mechanistic pathways (AMPK activation, autophagy enhancement, oxidative stress reduction) demonstrated primarily in animal and cell models, but human evidence specifically for longevity or lifespan extension is absent. Only 2 human RCTs exist, both focused on metabolic endpoints (glucose/lipids) rather than aging outcomes.

Quercetin shows plausible anti-aging mechanisms in animal and cellular models, particularly through senescence reduction and oxidative stress mitigation, but human evidence for longevity benefits remains limited to a single small observational study on telomere length. Efficacy in humans is not yet proven.

Resveratrol shows plausible anti-aging mechanisms (SIRT1 activation, antioxidant effects) and improves some age-related outcomes (bone density, skin appearance, neuroprotection in models), but human efficacy for longevity itself remains unproven. Evidence is primarily mechanistic or limited to surrogate markers rather than demonstrating extended lifespan or meaningful life extension in humans.

Alpha-lipoic acid shows plausible anti-aging mechanisms in animal models, particularly for mitochondrial function and oxidative stress, but human evidence for longevity is absent. The single human RCT showed no clinical benefit, and observational human studies found no cognitive or mood effects.

Melatonin shows plausible anti-aging mechanisms supported by animal studies and mechanistic reviews, but human evidence for longevity extension is lacking. Only one small feasibility RCT (n=40) in mild cognitive impairment was identified, with null efficacy results for cognition and oxidative stress.

Vitamin K2 shows plausible mechanisms for longevity support based on animal studies and mechanistic evidence, but human proof of efficacy for extending lifespan or preventing age-related decline remains absent. Only one small human RCT is registered (InterVitaminK, still ongoing), with existing human data limited to observational studies and bone health outcomes.

Milk thistle (silymarin/silibinin) shows promise for longevity in animal models through antioxidant and anti-inflammatory mechanisms, but human evidence for lifespan extension or longevity is absent. Current evidence is limited to small animal studies and in-vitro work demonstrating plausible anti-aging pathways.

Rhodiola rosea shows plausible anti-aging and longevity potential through multiple mechanistic pathways in animal and in-vitro studies, but human evidence for actual lifespan extension or aging reversal is absent. Only one small human RCT with indirect longevity markers exists.

Maca root shows plausible mechanisms for supporting age-related decline through mitochondrial function and hormone production in animal models, but evidence for human longevity is minimal and indirect. Only one human RCT exists, studying hypogonadism symptoms rather than longevity outcomes.

Black Seed Oil shows plausible anti-aging potential through antioxidant and anti-inflammatory mechanisms in animal and in-vitro studies, with one Drosophila study demonstrating lifespan extension at low doses. However, no human RCTs directly measuring longevity or lifespan outcomes exist, limiting proof of efficacy for this specific goal.

Elderberry shows plausible anti-aging mechanisms through antioxidant and anti-inflammatory pathways in human and animal studies, but lacks robust human RCT evidence directly demonstrating longevity or lifespan extension. Only one small human RCT exists for immune senescence markers.

Green Tea Extract (EGCG) shows consistent anti-aging mechanisms in animal studies and mechanistic research, including lifespan extension in obese rats and senescence reversal in cells, but human evidence for longevity is limited to 1 small RCT and observational studies on disease markers rather than actual lifespan or aging rate.

Psyllium husk shows plausible mechanisms for supporting longevity through gut microbiota modulation and anti-inflammatory effects, but evidence remains limited to 1 small human RCT on constipation and 3 animal studies. No human studies directly measure longevity outcomes or lifespan.

Spirulina shows plausible longevity benefits through antioxidant and anti-inflammatory mechanisms in animal models and yeast, but robust human evidence is lacking. Only one human RCT exists, focused on COVID-19 outcomes rather than lifespan or aging markers.

Fenugreek has not been studied for longevity as a primary outcome. Available evidence focuses on testosterone levels and metabolic markers in aging men, with no direct evidence of lifespan extension or longevity benefits in humans.

Glucosamine + Chondroitin has not been proven to extend longevity or prevent age-related disease in humans. While one large observational study (UK Biobank) associated glucosamine with reduced risk of several chronic diseases, the evidence remains primarily mechanistic (cell-based and animal models) or focused on joint pain rather than lifespan or aging biomarkers.

Vitamin E shows plausible mechanisms for longevity through antioxidant and anti-inflammatory pathways, but human evidence for life-extension or mortality reduction is absent or negative. Large meta-analyses found no effect on all-cause mortality despite decades of supplementation.

Iron supplementation is well-established for treating iron deficiency anemia, but evidence for longevity is sparse and contradictory. Human studies show iron corrects anemia effectively, but observational data suggest excess iron may increase oxidative stress and age-related disease risk.

Selenium shows plausible mechanisms for longevity through antioxidant and anti-inflammatory pathways, and observational studies associate low selenium with accelerated biological aging. However, no human RCTs have demonstrated that selenium supplementation actually extends lifespan or improves longevity outcomes.

Iodine is essential for thyroid function and brain development, but evidence for longevity benefits is indirect and largely mechanistic. No human RCTs demonstrate that iodine supplementation extends lifespan; existing evidence shows thyroid dysfunction relates to age-related disease risk, but causation and optimal dosing for longevity remain unproven.

Copper supplementation shows plausible mechanisms for longevity in animal models and one human observational study, but lacks rigorous human evidence. A single human observational study reported an association between dietary copper intake and longer telomeres in hypertension patients, while animal and mechanistic studies suggest copper supports mitochondrial function and antioxidant defense.

Chromium shows plausible mechanisms for supporting metabolic health and glucose control through improved insulin sensitivity, but human RCT evidence is weak and inconsistent. Age-related chromium depletion is documented, but supplementation has not demonstrated clinically meaningful longevity benefits in humans.

Fisetin shows consistent senolytic and anti-senescence effects across multiple animal models and in vitro studies, with emerging evidence from small human observational studies. However, no randomized controlled trials in humans exist, and proven efficacy for longevity extension in humans remains undemonstrated.

Sulforaphane shows promise for longevity in animal models with consistent mechanistic support through Nrf2 activation and mitochondrial function, but human efficacy for lifespan extension remains unproven. Evidence is primarily from C. elegans and rodent studies; no human randomized trials exist.

Astaxanthin shows promise for longevity-related outcomes in animal models and limited human studies, with consistent antioxidant and anti-inflammatory mechanisms, but human evidence remains sparse and mostly indirect (focused on aging-related biomarkers rather than lifespan or mortality).

Glutathione supplementation shows consistent immunomodulatory and metabolic benefits in animal and limited human studies, but evidence for longevity effects specifically is not proven. Only one human RCT exists, demonstrating improved insulin sensitivity but not lifespan or aging markers.

Boswellia shows plausible mechanisms for supporting longevity-related outcomes through anti-inflammatory and antioxidant pathways, but evidence for direct lifespan extension or aging reversal in humans is absent. Available human data focuses on age-related diseases (osteoarthritis, cognitive decline) rather than longevity itself.

TUDCA shows consistent neuroprotective and cellular stress-reduction effects in animal models and limited human studies, but lacks rigorous human RCT evidence for longevity specifically. One small open-label human RCT (n=13) demonstrates clinical benefit in ulcerative colitis, but longevity endpoints were not measured.

Shilajit shows plausible but unproven efficacy for longevity. One human RCT demonstrated improved skin perfusion and upregulation of extracellular matrix genes in middle-aged women, while a review suggests potential cognitive benefits via fulvic acid's tau-blocking properties, but no direct longevity outcomes have been measured.

Colostrum shows plausible mechanisms for supporting longevity through immune function and metabolic improvements, but human evidence for longevity-specific outcomes remains limited. One human RCT demonstrated reduced pro-inflammatory markers in older adults; broader lifespan or aging outcomes have not been rigorously studied in humans.

Beta-glucans show plausible immune-enhancing mechanisms in human studies, but lack robust evidence for longevity as a primary outcome. Only 3 human RCTs exist, with modest effects on respiratory infections and immune markers that haven't translated to demonstrated lifespan extension or aging-related outcomes.

Cordyceps shows plausible mechanisms for supporting longevity-related processes (autophagy, mitochondrial function, cellular senescence) primarily demonstrated in animal and in-vitro studies. However, human evidence is extremely limited—only one small human RCT exists, studying acute muscle stem cell responses to exercise, not longevity outcomes.

Reishi extends lifespan in C. elegans through autophagy induction and shows promise for age-related conditions in mechanistic studies, but human evidence is limited to two small RCTs examining fitness and immune function rather than longevity outcomes.

Chaga shows consistent anti-aging and longevity-related effects in animal models and cell studies, primarily through antioxidant and autophagy-promoting mechanisms, but human clinical trial evidence for longevity outcomes is absent.

Apigenin shows consistent anti-aging effects in multiple animal models through oxidative stress reduction and anti-inflammatory pathways, but no human longevity trials exist. Evidence is limited to rodent and invertebrate studies with mechanistic plausibility but unproven efficacy in humans.

Pterostilbene shows promising anti-aging mechanisms in cellular and animal models through SIRT1/AMPK activation and senescence reduction, but human efficacy for longevity remains unproven. Only one small human RCT exists, which showed null results for muscle regeneration.

Grape seed extract shows plausible anti-aging mechanisms in animal and in-vitro studies, particularly through antioxidant and anti-inflammatory pathways, but lacks rigorous human evidence. Only one small human RCT exists, and most longevity-relevant data comes from animal models or mechanistic studies.

Olive leaf extract and its phenolic compounds show consistent mechanistic promise for longevity-related pathways in preclinical models, but human evidence is minimal and insufficient to prove efficacy. Only one small human RCT exists, with mixed results that did not withstand multiple-testing correction.

MSM shows promise for longevity-related outcomes in animal models and limited human studies, but efficacy in humans for extending lifespan or promoting healthy aging remains unproven. Current evidence is insufficient to recommend MSM specifically for longevity based on rigorous human data.

Bromelain shows plausible anti-aging mechanisms in animal and cell studies, but human efficacy for longevity has not been demonstrated. The single human RCT tested only post-surgical recovery, not aging or lifespan.

Stinging nettle shows promise for longevity-related outcomes through antioxidant and anti-inflammatory mechanisms, primarily demonstrated in animal models and mechanistic studies. However, direct human evidence for longevity extension is absent; existing human data focus on diabetes management and symptom relief rather than lifespan or aging outcomes.

Mucuna pruriens shows plausible anti-aging and neuroprotective effects in animal models and disease-specific contexts (primarily Parkinson's disease), but lacks direct human evidence for longevity extension. No human RCTs have demonstrated lifespan extension or aging biomarker improvements.

Ecdysterone shows promise for longevity in animal models through autophagy induction and metabolic reprogramming, but human efficacy for lifespan extension remains entirely unproven. Only one Phase 1 human safety study exists; no human longevity or lifespan data are available.

Tribulus terrestris shows plausible but unproven effects on longevity-related markers in animal models, with limited human evidence restricted to sexual function and hormonal parameters in aging men rather than direct lifespan or aging outcomes.

Echinacea shows promising effects on immune cell populations and survival in aging animal models, but efficacy in humans for longevity remains unproven. Only one small human RCT exists, focused on immune markers rather than lifespan.

Lemon balm shows emerging promise for supporting cognitive function and neuropsychiatric symptoms in aging and dementia, but human evidence remains limited to small pilot trials with mixed results. No robust evidence directly demonstrates longevity extension in humans.

Schisandra chinensis shows plausible longevity-relevant effects (antioxidant, anti-inflammatory, autophagy regulation) supported by consistent animal and mechanistic studies, but direct human evidence for longevity or lifespan extension is minimal. Only one small human RCT (n=54) with modest results on muscle strength exists; the compound has not been tested for actual lifespan extension in humans.

CLA shows plausible mechanisms for longevity-related outcomes (bone health, muscle preservation, antioxidant effects) primarily demonstrated in animal and cell models, but human evidence is extremely limited and inconsistent. Only observational data and one small RCT exist in humans, with no definitive proof that CLA supplementation extends lifespan or robustly improves aging-related outcomes.

Methylene blue shows mechanistic promise for longevity via mitochondrial quality control and mitophagy activation in animal models, but lacks robust human clinical evidence demonstrating actual lifespan extension or meaningful longevity outcomes.

Lithium orotate shows promise for longevity and cognitive preservation through neuroprotective mechanisms in animal models and cell culture, but no human clinical trials have demonstrated efficacy for longevity endpoints. Evidence is primarily mechanistic and preclinical.

Pregnenolone shows plausible longevity-relevant mechanisms in animal and mechanistic studies, particularly for cognitive function and neuroprotection, but lacks human RCT evidence. No human trials demonstrate that pregnenolone supplementation extends lifespan or improves aging outcomes.

SAMe shows plausible longevity mechanisms in animal and cell models, particularly through methionine metabolism and epigenetic regulation, but has no direct human evidence proving it extends lifespan or delays aging.

Astragalus shows plausible anti-aging mechanisms in animal and in-vitro studies, with one meta-analysis demonstrating telomere elongation in humans; however, this telomere effect did not translate to functional improvements in frailty or inflammation, and only 1 human RCT exists on longevity-specific outcomes.

Oral hyaluronic acid shows promise for skin aging parameters in a meta-analysis of human RCTs and animal models, but human evidence remains limited and the connection to longevity is unproven. Efficacy is plausible but not established for the stated goal of longevity.

Butyrate shows plausible mechanisms for promoting longevity through microbiota-mediated pathways, but proven efficacy in humans is limited to small observational studies and one pediatric RCT focused on obesity rather than lifespan extension. Most evidence comes from animal models and mechanistic studies.

Betaine shows mechanistic promise for longevity through effects on methylation, homocysteine reduction, and mitochondrial function, but human evidence specifically demonstrating lifespan or aging outcomes remains absent. Animal studies suggest potential benefits, but efficacy in humans is unproven.

Lion's Mane shows promise for longevity and age-related health in animal models and limited human studies, with consistent effects on neuroprotection and cognitive function. However, human evidence remains sparse (only 3 RCTs identified) with small sample sizes, so efficacy for human longevity is plausible but not yet proven.

Alpha-GPC shows plausible cognitive and longevity-related benefits through animal studies and one small human RCT, but human evidence is severely limited. No rigorous, large-scale human trials demonstrate proven efficacy for longevity or age-related cognitive decline.

Panax ginseng shows promise for longevity through multiple mechanistic pathways including antioxidant, anti-inflammatory, and neuroprotective effects in animal and cell culture studies, but human evidence remains minimal with only one RCT identified across 50 total articles.

Piracetam has been studied for longevity and cognitive aging, but human evidence is weak and contradictory. While some mechanistic studies suggest mitochondrial benefits in aged animals, clinical trials show no significant cognitive improvements and one large observational study found increased dementia risk associated with piracetam use.

Aniracetam shows consistent cognitive and neuroprotective effects in animal models and limited human observational data, but lacks rigorous human RCTs specifically testing longevity or lifespan extension. Evidence suggests potential benefits for age-related cognitive decline, but human efficacy for longevity is not proven.

Uridine has been studied primarily in Alzheimer's disease models, not directly for longevity. Limited human evidence suggests uridine may support cognitive function in early AD through synaptic membrane synthesis, but no human studies directly measured lifespan or aging biomarkers relevant to longevity.

Vinpocetine shows promise for longevity through cellular anti-aging mechanisms in in-vitro and animal studies, but human evidence is limited to small observational studies and older clinical trials with weak methodology. Efficacy in humans remains plausible but unproven.

NSI-189 shows promise for longevity-related outcomes in animal models through mitochondrial protection and neurogenic mechanisms, but no human studies specifically examining longevity or lifespan exist. Evidence is limited to rodent studies demonstrating cognitive and neuroprotective benefits.

DMAE shows potential for skin aging markers in limited human studies and animal models, but efficacy for longevity—the stated goal—remains unproven. No human studies demonstrate life-extension effects; animal lifespan data showed no benefit.

Oxiracetam shows consistent cognitive and memory benefits in animal models and preliminary human studies, but direct evidence for longevity effects is absent. No human trials demonstrate extended lifespan or aging-related longevity outcomes.

L-theanine shows consistent lifespan extension and anti-aging effects in animal models (C. elegans and rodents) through multiple mechanistic pathways, but human efficacy for longevity remains unproven. A single epidemiological study suggests green tea (containing L-theanine) associates with better aging outcomes, but no human RCT has directly tested L-theanine supplementation for longevity.

L-Tyrosine shows promise for supporting thermoregulation in older adults through enhanced sympathetic responses, but evidence for longevity benefits is limited to mechanistic studies in animals. No human studies directly assess lifespan or aging outcomes.

L-Glutamine shows plausible mechanisms for longevity-related processes (gut barrier integrity, mitochondrial function, antioxidant capacity) supported by observational metabolomics data and small human RCTs, but no direct evidence that glutamine supplementation extends lifespan or improves longevity outcomes in humans.

5-HTP has not been proven to extend lifespan or slow aging in humans. A single small RCT (n=30) showed improved cognitive function and mood in older adults over 12 weeks, but this does not constitute evidence for longevity. Most evidence comes from animal studies and mechanistic research showing 5-HTP's role in serotonin metabolism and age-related neurological changes.

GABA shows plausible mechanisms for longevity through cortical stabilization in aging and effects on muscle preservation and neuronal function, but evidence for direct human longevity benefit remains limited to observational and mechanistic studies. One human RCT exists (sarcopenia in mice extrapolated to humans), but robust human proof of life-extension or healthspan improvement is lacking.

Taurine shows plausible mechanisms for longevity and age-related health through antioxidant and mitochondrial effects, but human evidence remains limited to small observational studies and a few modest RCTs. No large-scale human trials have definitively proven lifespan or healthspan extension.

D-Aspartic acid shows plausible mechanisms relevant to aging and longevity through NMDAR modulation and antioxidant effects, but evidence for human longevity outcomes is absent. Only animal studies on reproductive aging exist; no human trials have assessed lifespan, healthspan, or aging biomarkers.

L-carnosine shows plausible mechanisms for longevity support (anti-glycation, antioxidant, mitochondrial protection) demonstrated consistently in animal models and mechanistic studies, but lacks any human RCT evidence or human longevity data. Efficacy for extending human lifespan remains unproven.

Tryptophan supplementation shows plausible mechanisms for supporting longevity-related outcomes (circadian rhythm regulation, stress hormone reduction, metabolic adaptation) demonstrated primarily in animal models and small human studies, but human efficacy for longevity itself remains unproven.

L-Serine shows neuroprotective mechanisms in cell culture and one small human ALS trial (n=20), but lacks rigorous human RCT evidence for longevity. Efficacy is biologically plausible but unproven in humans for lifespan or aging outcomes.

Tirzepatide has not been directly studied for longevity as a primary outcome. Evidence is limited to mechanistic studies and surrogate markers (weight loss, glucose control, mitochondrial function) in animals and short-term human trials that suggest potential longevity-relevant benefits, but no human studies demonstrate actual lifespan extension or longevity outcomes.

Exenatide shows neuroprotective effects in animal models and early-stage human trials for neurodegenerative diseases, but human efficacy for longevity is not yet proven. A large Phase 3 Parkinson's trial showed no benefit on primary motor outcomes.

Ghrelin shows biological effects on aging-related muscle loss and appetite regulation in humans, but evidence for longevity benefits is limited to mechanistic studies and observational findings. No human RCTs directly demonstrate that ghrelin supplementation extends lifespan or healthspan.

Matrixyl (palmitoyl pentapeptide-4) shows promise for skin aging in two small human RCTs and multiple animal/cell studies, but evidence of efficacy for longevity itself is limited to skin-level outcomes (wrinkles, photoaging markers) with no human data on systemic aging or lifespan effects.

Nesfatin-1 shows promise for longevity-related outcomes in animal models through anti-inflammatory, anti-apoptotic, and cellular senescence reduction pathways, but human evidence is limited to observational studies with no RCTs demonstrating longevity benefits in humans.

NPY shows consistent effects on autophagy and cellular aging mechanisms in animal and cell culture studies, but human efficacy for longevity is not proven. Evidence suggests NPY may act as a longevity regulator, but only one human observational study exists, and it focused on a rare genetic disease rather than normal aging.

Orexin-A shows plausible mechanisms for supporting cognitive function and healthy aging in animal and limited human studies, but efficacy for human longevity is not yet proven. Evidence is preliminary and mostly indirect.

P21 is a cell cycle checkpoint protein studied primarily in animal models for its role in neural stem cell senescence and neurogenesis. While multiple animal studies show that reducing p21 expression can promote neurogenesis and improve cognitive outcomes in aging models, there are no human trials demonstrating that p21 modulation actually extends lifespan or improves longevity outcomes in people.

PACAP shows plausible neuroprotective and anti-aging potential in multiple animal models and mechanistic studies, but lacks human RCT evidence for longevity. Current evidence is insufficient to prove efficacy for extending human lifespan.

Pramlintide shows promise for longevity through neuroprotective effects in animal models and observational human data linking amylin to brain health, but no human RCTs have directly tested its efficacy for aging or longevity outcomes.

Survodutide is a GLP-1/GIP dual agonist studied primarily for metabolic dysfunction and weight loss, not directly for longevity. No human studies specifically measure longevity outcomes, lifespan extension, or aging biomarkers in the abstracts provided.

Thymulin shows promise for supporting immune function and T-cell mediated immunity in aging, but proven efficacy for longevity in humans remains unestablished. Evidence is primarily mechanistic and observational rather than from rigorous clinical trials.

NAD+ shows promising theoretical mechanisms for longevity in animals and cellular models, but there are zero human randomized controlled trials demonstrating that NAD+ supplementation actually extends lifespan or improves longevity in humans. All efficacy claims rest on preclinical evidence.

Calcium intake is associated with reduced fall risk and improved bone health markers in observational studies, but evidence for longevity benefit remains limited. Meta-analyses show no meaningful effect on all-cause mortality or cardiovascular outcomes.

Manganese supplementation shows promise for lifespan extension and stress resistance in animal models and cell culture, but lacks human RCT evidence. One human observational study demonstrates radioprotective effects in fruit flies, while C. elegans and fibroblast studies suggest antioxidant mechanisms, but efficacy in humans for longevity remains unproven.

Vitamin B1 deficiency is associated with cognitive decline and neurodegenerative processes, but evidence for B1 supplementation improving longevity or age-related outcomes in humans is lacking. Only one small pilot RCT exists, and most evidence is observational or mechanistic rather than demonstrating proven longevity benefits.

Vitamin B2 (riboflavin) shows promise for neuroprotection and stroke recovery in animal and small human studies, but evidence for longevity benefit remains largely indirect and unproven in humans. No large-scale RCTs demonstrate that B2 supplementation extends lifespan or prevents age-related decline.

Luteolin shows consistent anti-aging and neuroprotective effects in animal models and cell studies, with one human observational study demonstrating associations with reduced phenotypic age acceleration. However, no rigorous human RCTs directly testing longevity or lifespan extension exist.

Ginger shows promising longevity-related effects in animal models and mechanistic studies, with one nematode study demonstrating 23% lifespan extension. However, no human RCTs have directly tested ginger for longevity outcomes, limiting proof of efficacy in humans.

Cinnamon shows promise for longevity in animal models through effects on insulin signaling and metabolic health, but lacks meaningful human evidence. The single human RCT found no benefit on cardiometabolic outcomes.

Vitamin K1 shows plausible but unproven benefits for longevity through mechanisms related to cardiovascular health, bone density, and physical function in observational studies. However, randomized controlled trials have failed to demonstrate clinically meaningful improvements in key longevity-related outcomes.

Lycopene shows plausible promise for longevity through antioxidant and anti-inflammatory mechanisms, with consistent benefits observed in animal studies and limited human data. However, efficacy in extending human lifespan or healthspan has not been proven—only biomarker improvements and disease risk reduction are demonstrated.

Zeaxanthin is studied primarily for eye health and age-related macular degeneration (AMD) prevention, not directly for longevity. While observational data suggests associations between serum zeaxanthin and reduced eye disease risk, and a few small RCTs show benefits for eye-specific outcomes, there is no direct evidence that zeaxanthin supplementation extends lifespan or improves longevity markers in humans.

Vitamin A supplementation shows plausible biological links to longevity through immune function and antioxidant mechanisms, but human evidence for life extension or measurable lifespan benefit is absent. Studies demonstrate correlations between carotenoid/vitamin A status and age-related health markers, but no direct proof that supplementation extends human lifespan.

Piperine shows age- and sex-dependent effects on healthspan in fruit flies, but there is no human evidence demonstrating efficacy for longevity. Animal data suggests potential but falls short of proof in humans.

Moringa oleifera shows antioxidant and anti-inflammatory properties with potential lifespan extension in model organisms, but human efficacy for longevity remains unproven. Evidence consists primarily of in-vitro studies, animal models, and reviews with only 1 human RCT (on soybean fertilizer, not human health) and 1 human observational study (on leukemia cells, not a longevity outcome).

DHEA levels decline with age and correlate with aging markers, but human evidence for DHEA supplementation improving longevity is absent. A recent Mendelian randomization study found DHEA-s was actually associated with shorter lifespan in men, contradicting the anti-aging hypothesis.

Caffeine shows mixed and inconsistent effects on cognitive function and longevity outcomes in humans. While some observational studies suggest associations between coffee/caffeine consumption and preserved cognition in aging, multiple human RCTs and large observational studies report null or negative cognitive effects, and no human studies demonstrate improvements in lifespan or mortality.

BPC-157 has only been studied for longevity-related effects in animal models and honeybees, with no human trials demonstrating anti-aging or lifespan benefits.

CJC-1295 has not been studied for longevity in humans; the only available evidence is a single 2006 animal study in GHRH-deficient mice showing normalized growth parameters, which does not address aging or lifespan extension.

KPV has not been studied for longevity in humans. The available evidence is limited to one animal study on vascular calcification and one review article mentioning KPV in the context of wound healing—neither directly addresses longevity outcomes.

No evidence that Melanotan 1 improves longevity. The only human data shows afamelanotide (an α-MSH analogue related to Melanotan 1) did NOT improve bone mineral density in a real clinical trial, and unregulated Melanotan 1 poses serious public health risks.

Gonadorelin (GnRH agonist) has not been studied for longevity in humans. The available evidence focuses on reproductive function, cancer treatment, and puberty management—not aging or lifespan extension.

There is no proven efficacy of Cardiogen for longevity in humans. The limited evidence consists of small animal studies and in-vitro research showing stimulation of cell proliferation and apoptosis modulation, but these findings have not been translated to demonstrated lifespan extension or human longevity outcomes.

Chonluten has only been studied in vitro in human cell cultures, showing modest anti-inflammatory effects on monocytes. No human trials, animal studies, or clinical efficacy data exist for longevity.

Bronchogen shows stimulatory effects on tissue cultures in aged rats and human cell cultures, but no human clinical trials exist. Efficacy for longevity in living humans remains unproven.

5-Amino-1MQ has not been studied for longevity in humans or animals; the only available evidence is a single in-vitro study showing anti-proliferative effects in cervical cancer cells. No efficacy for longevity has been demonstrated.

IGF-1 LR3 has not demonstrated efficacy for longevity in the available evidence. Two animal studies show mixed results: one found no cognitive preservation despite amyloid plaque remodeling, and the other examined muscle growth regulation without addressing lifespan outcomes.

No efficacy data exists for oxytocin and longevity. Only a protocol paper describing a planned study design was found; no results are reported, making it impossible to assess whether oxytocin actually works for this goal.

Decapeptide-12 has not been studied for longevity in humans or animals. The only available evidence concerns skin brightening and photodamage reversal, which is not a longevity endpoint.

Retinalamin is mentioned as one of several peptide bioregulators being studied for geroprotection, but the available abstract provides no specific efficacy data, effect sizes, or clinical outcomes to demonstrate that it actually works for longevity.

No human evidence exists for boron supplementation and longevity. Animal studies show boron affects bone metabolism and reproductive enzymes, but these are not established markers of lifespan extension or aging delay.

Saw palmetto has no demonstrated efficacy for longevity. All evidence concerns benign prostatic hyperplasia (BPH) in aging men, not lifespan extension or longevity outcomes.

Biotin has not been demonstrated to extend longevity or meaningfully improve aging-related outcomes in humans. The evidence base consists primarily of mechanistic reviews and animal studies in non-aging contexts, with no human RCTs or longitudinal studies measuring lifespan or healthspan.

DIM has not been tested for longevity in humans. All available evidence comes from review articles and a single C. elegans model study showing improved reproductive aging markers, which does not translate to proven longevity effects in humans.

Turkey Tail mushroom extract shows cytotoxic activity against melanoma cells in laboratory studies, but there is no clinical evidence demonstrating efficacy for longevity in humans. The single available study is an in-vitro cell culture experiment with no relevance to aging or lifespan extension.

A single review article describes a C. elegans study showing that maral root extract and turkesterone may extend lifespan and enhance stress resilience in a model organism, but no human efficacy data exists and the actual study results are not fully detailed in the abstract.

Valerian root lacks evidence for longevity and has failed to demonstrate efficacy for insomnia in rigorous human trials. The limited animal study on aging showed promise, but this does not translate to proven human benefit.

D-Ribose for longevity lacks human clinical evidence. Only one review article directly addresses D-Ribose and mitochondrial function; all other abstracts discuss related metabolic pathways (NAD+, pentose phosphate pathway, PARP-1) but do not study D-Ribose supplementation or its effects on aging/longevity.

Forskolin has not been studied as a standalone intervention for longevity in humans. The single human trial combined it with 6 other ingredients, making efficacy attribution impossible. Mechanistic studies in animals and cells show forskolin increases cAMP signaling, which may theoretically influence aging pathways, but no direct evidence of longevity benefit exists.

Peppermint oil shows theoretical potential for longevity through antioxidant and antitumor properties in laboratory studies, but there is no human evidence demonstrating efficacy for lifespan extension or longevity-related outcomes.

Phosphatidylserine (PS) appears in longevity research primarily as a mechanistic component involved in cellular recycling pathways (autophagy, efferocytosis) rather than as a direct longevity-extending intervention. No human studies demonstrate that PS supplementation extends lifespan or healthspan.

Only one review article exists on Noopept for longevity, reporting that combined self-massage and Noopept improved functional state in elderly teachers, but no rigorous human trials, animal studies, or mechanistic evidence for longevity specifically are available.

No evidence demonstrates that pramiracetam extends longevity or lifespan in any organism. Available abstracts discuss cholinergic mechanisms and EEG normalization in aged rats, but neither study measured or reported longevity as an outcome.

Ornithine supplementation shows tissue-specific effects on ovarian putrescine in aged mice, but efficacy for longevity or fertility outcomes was not demonstrated. This is preliminary animal-only evidence with no human trials.

Retatrutide has not been studied for longevity in humans. All evidence is from animal models or mechanistic reviews, showing only potential neuroprotective effects and metabolic benefits that are theoretically relevant to aging but do not directly demonstrate improved lifespan or longevity outcomes.

No evidence that Adipotide improves longevity. The single identified abstract does not study Adipotide and does not address longevity outcomes.

There is no human evidence that cortistatin improves longevity. Animal studies show cortistatin can impair learning and memory, and one animal study suggests reduced cortistatin may be associated with cognitive deficits in Alzheimer's models—results that actually contradict longevity benefits.

IGF-1 DES has not been studied for longevity outcomes in humans. Available evidence only documents age-related changes in IGF-1 responsiveness in aging tissues, without demonstrating that IGF-1 DES treatment extends lifespan or improves longevity-related markers.

Lanreotide is a somatostatin analog used to treat neuroendocrine tumors and acromegaly, but there is no evidence it improves longevity as a primary outcome. The available literature addresses disease management and safety, not lifespan extension.

Linaclotide has not been studied for longevity. The available evidence examines its use for constipation management in older adults and its safety profile, but contains no data on lifespan, aging markers, or longevity-related outcomes.

Lixisenatide has not been studied for longevity or lifespan extension in humans. Available evidence focuses on type 2 diabetes and cardiovascular safety, with no direct evidence of longevity benefits.

Octreotide has not been shown to improve longevity in humans. Studies examine its use in treating specific diseases (acromegaly, neuroendocrine tumors) and its mechanistic effects on cellular processes, but no evidence demonstrates direct life-extension or longevity benefits in any population.

Pemvidutide was not studied in any of the 50 abstracts provided. The abstracts discuss GLP-1 receptor agonists, GIP/GLP-1 dual agonists, and related compounds (semaglutide, tirzepatide, liraglutide, cotadutide, exendin-4), but pemvidutide specifically does not appear in any abstract title or content shown.

Peptide YY shows no proven efficacy for longevity. The available evidence examines PYY's role in appetite regulation and metabolic parameters, but does not demonstrate that modulating PYY levels extends lifespan, improves healthspan, or produces anti-aging effects in humans.

No human efficacy data exists for setmelanotide and longevity. The abstracts mention setmelanotide only as a treatment for genetic obesity disorders (leptin receptor deficiency, Bardet-Biedl syndrome), not as a longevity agent. There is no evidence this compound extends lifespan or improves aging-related outcomes.

Teriparatide has not been studied for longevity as a health goal in any of the 50 identified abstracts. All evidence concerns fracture risk reduction and bone density in osteoporosis, which are disease-specific outcomes unrelated to lifespan or aging processes.

Vosoritide is studied for achondroplasia (dwarfism) treatment, not longevity. No abstracts demonstrate effects on lifespan, aging, or longevity outcomes in any organism.

C-10 has no demonstrated efficacy for longevity. The retrieved abstracts do not contain evidence that C-10 improves lifespan, aging markers, or longevity-relevant outcomes in humans or animals.

No human evidence demonstrates that vitamin B6 improves longevity. One review suggests B6 supplementation may help manage homocysteine levels in early Alzheimer's disease, but this is a mechanistic proposal without clinical efficacy data. The second study measured B6 metabolism in piglets with no longevity outcomes reported.

Apoaequorin has been studied for cognitive function in aging, but the only human RCT reported no significant effects on verbal learning and working memory, while animal studies show mixed results on fear memory with unclear relevance to human longevity.

No evidence demonstrates that sea moss extract improves longevity in humans. Study 1 is a review describing potential biological properties in laboratory and animal models, while Study 2 examines bacterial survival on beaches—neither addresses longevity outcomes.

Dandelion root extract shows promise in killing cancer cells in laboratory studies, but there is no evidence it improves longevity in humans. The available research is limited to cancer cell cultures and one small study in leukemia patients with no longevity outcomes measured.

Yellow Dock (Rumex japonicus) has only one animal study showing it may reduce inflammatory markers in chemically-induced colitis in mice; no human evidence exists for longevity benefits.

There is no evidence that chlorophyll improves longevity in humans. Available studies only characterize chlorophyll compounds in food sources and show in-vitro enzyme inhibition, with no human trials demonstrating longevity benefits.

Custom orthotics have not been studied for longevity. The single available study examined their effects on foot pain and function in psoriatic arthritis patients, which is unrelated to lifespan or aging outcomes.